Background: Vitamin D, a hormone that acts through the nuclear vitamin D receptor
ubiquitously expressed. Epidemiological studies have consistently shown an association between low vitamin D and increased aggressive pathology and mortality in prostate cancer (PCa) but not with PCa incidence. [5] [6] [7] [8] [9] The recent Vitamin D and Omega-3 Trail (VITAL) study did not show an effect of vitamin D on PCa incidence, but when the first 2 years of follow-up were excluded, there was a significant 25% reduction in all-cancer mortality in the vitamin Dsupplemented patients. 10 As the majority of PCa is indolent, the null relationship of vitamin D with PCa incidence is not as clinically relevant as its relationship with disease progression.
In the prostate, genomic targets of vitamin D have been suggested to decrease tumor aggressiveness by decreasing inflammation and proliferation and increasing apoptosis and differentiation. 11 Studies of vitamin D in PCa cells in vitro and in animal models support antitumor activities. [12] [13] [14] [15] Previous work from our lab and others have shown that vitamin D increases the expression of tumor-suppressive microRNAs (miRNAs), small noncoding RNA (ncRNA) that regulate translation of messenger RNAs (mRNAs). 16, 17 As miRNAs are generally downregulated in PCa, upregulation of miRNAs by vitamin D may play a role in its antitumorigenic effects in prostate. 17 Very little is known about vitamin D regulation of other ncRNA species. A recent paper showed vitamin D-regulation of melanoma-associated long ncRNAs in keratinocytes. 18 As roles are emerging for several non-miRNA small ncRNAs in cancer, such as small nucleolar RNA (snoRNA), transfer RNA (tRNA) fragments, and PIWI-interacting RNA (piRNA), it will be important to understand the effects of vitamin D on the expression of these molecules in the prostate. deidentified. 20 All patients in for sequencing were Caucasian and had a Gleason score of 3 + 3 or 3 + 4. For a 3 to 8 week period before surgery, patients in this study received 400 or 40 000 IU of liquid oral vitamin D3 daily. Prostatectomy tissue from the peripheral and transitional zones was freshly frozen and stored at −80°C. Serum 25D (cholecalciferol) and prostatic 1,25D (calcitriol) were measured by liquid chromatography-tandem mass spectrometry and enzyme immunoassay, respectively, as part of the original trial (Table 1) . 20 Primary prostate epithelial cells (PrE) were isolated from deidentified benign prostatectomy tissue as determined by a pathologist and grown in PrEGM media (Lonza, Basel, Switzerland) for one passage on collagen-coated plates 17 ; the University of Illinois at Chicago (UIC)
| MATERIALS AND METHODS

| Patient specimens
Institutional Review Board approved protocol #2011-1138.
| Laser capture microdissection RNA isolation and small-RNA sequencing
Laser capture microdissection (LCM) RNA collection was performed as described. 21 Approximately 1000 glands were collected from each patient. RNA was isolated using the RNAqueous-Micro Kit (Ambion, Foster City, CA). Sequencing libraries were constructed using 500 ng of in high output mode using TruSeq Rapid sequencing kit v3 (Illumina).
Adapter sequences were removed using cutadapt, 22 and 3′ end trimming of bases with a Phred quality score less than 20. Reads less than 17 base pairs (bp) were discarded. For alignment, miRNA stemloop sequences were retrieved from miRBase (release 21), 23 piRNA sequences from piRNABank, 24 and ribosomal RNA (rRNA), small nuclear RNA (snRNA), snoRNA, and tRNA sequences from Ensembl version 90 (Hinxton, United Kingdom). 25 Reads were aligned to small ncRNA sequences using SHRIMP 2.2.3 aligner in ungapped local alignment mode with seed size of 14 allowing two mismatches. 26 The highest scoring match strata were reported. Counts were generated using a custom script so that reads mapping to multiple ncRNA species were designated in the hierarchical order: miRNA, rRNA, snoRNA, snRNA, tRNA, or piRNA. If one read sequence mapped to multiple of one species of small RNA, the read was split proportionally. Custom code is accessible at https://github.com/sgao30/ smallRNAseq. Differential small RNA expression was calculated using EdgeR. 27, 28 Small-RNA sequencing and counts are deposited at NCBI GEO accession number GSE124589.
| The Cancer Genome Atlas small-RNA sequencing data
Access to The Cancer Genome Atlas (TCGA) data was obtained through dbGaP (project# 15240). We utilized small-RNA sequencing files from the whole prostate in the prostate adenocarcinoma (PRAD) data set. We reanalyzed 11 benign small-RNA sequencing samples from Roswell Park using our alignment pipeline. Adapter-trimmed read sequences (both aligned and unaligned) were extracted using bedtools bam2fastq. 29 Since TCGA small-RNA sequencing reads are 15 to 30 bp, we only used reads 17 to 30 bp in our data set for comparisons.
| piRNA sequence characterization
Consensus sequences of piRNAs with an average greater than 100 CPM (99 piRNAs and 92 piRNAs in control and high vitamin D groups, respectively) were created using the Berkley WebLogo Tool (https://weblogo.berkeley.edu/logo.cgi). 30 The presence of a secondary biogenesis signature was assessed using the piPipes_smallR-NA_intersect script from the piPipes package. 31 Genomic locations (hg19) of piRNAs expressed greater than 100 CPM were determined using bedtools intersect 29 with 1 bp overlap for the locations of piRNA sequences from piRBank, 24 and UCSC genome annotations, 32 RepeatMasker, 33 or pooled/generic testis piRNA clusters from human testis in the piRNA cluster database (converted to hg19 with UCSC liftover). 34, 35 piRNAs with multiple locations were designated in the following order: coding sequence, 3′-untranslated region (3′-UTR), 5′-UTR, intron, piRNA cluster, and repeat DNA sequence. 46 ChIP-sequencing data and peak locations are deposited at NCBI GEO accession number GSE124576. quantity was calculated by the −ΔΔC t method, using GAPDH or HPRT1 for normalization.
| Chromatin immunoprecipitation-sequencing
| Immunostaining
| In situ hybridization
The miRCURY LNA microRNA ISH Optimization Kit (Exiqon, Vedbaek, Denmark) was followed with modifications. 
| Statistical analysis
All statistics not yet mentioned were performed in GraphPad Prism 8.0.0. A value of P < 0.05 is considered significant.
| RESULTS
| LCM small-RNA sequencing of prostate epithelium
The patients in the current study were from the control (400 IU/day) and high-dose vitamin D (40 000 IU/day) groups of a clinical trial of cholecalciferol (25(OH) 2 D 3 ) supplementation for 3 to 8 weeks before radical prostatectomy. 20 This inactive prohormone is the form of vitamin D that is predominant in circulation and permitted patients to achieve supra-physiological levels of prostatic vitamin D without adverse effects on clinical parameters of calcium or phosphate homeostasis. 20 Characteristics of the patients, including vitamin D metabolite levels in serum and prostate tissue at the time of radical prostatectomy, are shown in Table 1 . LCM was used to isolate benign epithelium from the prostatectomy tissues followed by total RNA isolation and sequencing.
Small-RNA sequencing reads were trimmed and aligned to a reference library of annotated human pre-miRNA, rRNA, snoRNA, snRNA, tRNA, and piRNA sequences. In total, 68% to 80% of reads per sample mapped to small ncRNA (Table SI) , and in the small percentage of cases (<0.01%) where a read mapped equally well to multiple small ncRNA classes, the class was assigned ( Figure 2B and Table SI) . Seven miRNAs, including miR-146a and miR-595, and one snRNA were also differentially expressed (Table SIII) . from PCa (PC-3, LNCaP, 22RV1, and LAPC4) ( Figure 3D ). These results suggest that PIWIL proteins are expressed in prostate tissue, and therefore, the piRNAs expressed in prostate tissue may be functional.
| Comparison of small-RNA sequencing of LCM epithelium to the whole prostate in TCGA
We compared the small ncRNA profiles from LCM benign prostate epithelium to the small-RNA sequencing profiles of benign whole Figure 4A ). In contrast, there were marked differences in the profiles of another small ncRNA between the data sets ( Figures 4B and S2B ). This was apparent for piRNAs, suggesting that piRNA expression profiles may be strongly affected by the stromal bias in TCGA data ( Figure 4B ). To test for epithelial expression, we selected two piRNAs (<30 bp) which were highly expressed in our LCM samples (>1000 CPM-mapped piRNA) and poorly expressed in TCGA samples (<10 CPM-mapped piRNA) for in situ hybridization on a tissue microarray containing prostatectomy tissue from 32 patients. These piRNAs are only expressed from one genomic location; piR-has-15603 is unannotated and piR-has-9286 is intronic. Both piRNAs were detected in prostate and consistently showed higher expression in prostate epithelium than surrounding stroma ( Figure 4C ). These results demonstrate the value of performing LCM in studies of prostate tissue specimens.
| Comparison of small-RNA sequencing of LCM epithelium to small-RNA sequencing of PrE cells
Small-RNA sequencing data was also collected from benign PrE (Table SIV) . Although more binding sites were significantly decreased following 1,25D treatment, the fold change (FC) of these sites (avg. log 2 (FC) = 1.48)
was less than at sites with significant increases in VDR binding (avg. (Table SV) . TDRKH (Tudor and KH domain-containing protein) is a
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Comparison to TCGA PRAD benign whole tissue small-RNA sequencing data. Heatmaps of (A) miRNA and (B) piRNA expression in our LCM-collected and in TCGA benign prostate whole tissue small-RNA sequencing data. The log (CPM) for individual small RNAs within the samples (CPM reads mapped to each small RNA type) was calculated. Hierarchical clustering used Spearman correlation as the distance metric. Small RNA are ordered by average log (CPM) expression level in the LCM-collected epithelium. (C) In situ hybridization for two piRNAs highly expressed in our LCM-collected data and expressed at very low levels in TCGA data. H&E stain of an adjacent section is included for reference. No probe and scrambled probe controls are shown on the left. CPM, counts per million; DAPI, 4′,6-diamidino-2-phenylindole; H&E, haemotoxylin and eosin; LCM, laser capture microdissection; miRNA, microRNA; piRNA, PIWI-interacting RNA; TCGA, The Cancer Genome Atlas. [Color figure can be viewed at wileyonlinelibrary.com] PIWIL adapter protein with an intronic VDR peak ( Figure S5A ). Four individual patient-derived PrE cell lines showed elevated expression of TDRKH mRNA when treated with vitamin D (Figure S5B ). An increase in TDRKH protein was observed in vitamin D-treated RWPE1 prostate epithelial cells ( Figure S5C ). This suggests that TDRKH is a vitamin D-regulated gene in prostate epithelium.
There was a high percentage of VDR-ChIP peaks that showed decreased binding after 1,25D treatment. We compared these genomic locations to those where VDR binding increased. Gene set enrichment analysis using GO and Kegg terms were performed on genes with transcription start sites within 5 kb of a peak. Genes near peaks that were higher in control cells were enriched in pathways related to translation, oxidative phosphorylation, ncRNA processing, and p53 signaling ( Figure 7A ). Genes near peaks that were higher after 1,25D treatment were enriched in pathways related to morphogenesis and motility ( Figure 7B ). The central 200 bp of VDR-ChIP peaks were evaluated for the enrichment of transcription factor binding sites. The consensus binding site for VDR was enriched under both conditions. In the peaks that were significantly higher in control cells, ETS transcription factor binding sites, such as Elk4 and ETS, were the most highly enriched ( Figure 7C ). Conversely, in peaks that were significantly higher under 1,25D treatment, bZIP transcription factor binding sites, such as Atf3 and AP-1, were the most highly enriched ( Figure 7D ).
| DISCUSSION
We investigated the associations between vitamin D and ncRNA in prostate epithelium using small-RNA sequencing of LCM-collected tissue from a clinical trial of high-dose vitamin D supplementation, and VDR ChIP-sequencing of primary prostate epithelial cells. We previously reported that vitamin D upregulates miR-100 and miR-125b in prostate epithelium, which may contribute to its antitumor effects. 17 In prostate stroma, vitamin D upregulated miRs, including miR-21, and miR biogenesis gene DICER. 47 Vitamin D has also been shown to also modulate miRNA expression in other tissues and serum. 16 However, the effect of vitamin D on the majority of small ncRNA species is unknown.
Our results suggest that piRNAs are expressed in normal benign prostate epithelium, and associated with vitamin D. 65 In predicting whether vitamin D-induced changes in prostatic piRNAs are antitumorigenic, it is important to consider that some studies suggest that both low and high serum levels of vitamin D increase the risk of developing PCa. 66 In the clinical trial that our LCM tissues were obtained from, there was decreased Ki67 proliferation marker expression in the prostates with higher vitamin D, suggesting reduced tumor proliferation. 
